Sign up
Pharma Capital

True Leaf taps veterinary cannabinoid advocate to its advisory board

Conny Mosley is vice president of the Canadian Association of Veterinary Cannabinoid Medicine with more than 20 years experience as a veterinarian
Conny Mosley
Mosley (pictured) heads the integrative pain management service at the VCA Canada 404 Veterinary Emergency and Referral Hospital in Ontario

True Leaf Medicine International Ltd (CSE:MJ) (OTCQX:TRLFF) (FSE:TLA), the cannabis-for-pets wellness brand, added a new member to its veterinary advisory board.

Conny Mosley is vice president of the Canadian Association of Veterinary Cannabinoid Medicine and joins the True Leaf board with more than 20 years experience in the industry.

She also heads the integrative pain management service at the VCA Canada 404 Veterinary Emergency and Referral Hospital in Ontario, which works to improve quality of life for pets with chronic pain.

READ: True Leaf taps Mars Petcare exec Kevin Cole to lead its pet division

“We are proud to welcome another top veterinarian dedicated to advancing cannabis-based therapies for pets to the True Leaf Veterinary Advisory Board,” CEO Darcy Bomford said. “Our commitment to be the leading global cannabis-for-pets brand starts with product excellence. Dr. Mosley will be a key member of our team as we work towards launching a best-to-market CBD product for pets and begin development on a veterinary exclusive line.”

Mosley has pushed Health Canada to allow cannabidiol to be classified as a veterinary health product, which would permit the British Columbia company to market CBD pet products in Canada.

“Veterinary clinics across the country are seeing strong client demand for legal and effective medicinal cannabis products for pets,” Mosley said. “I joined True Leaf because its team of pet industry veterans are at the forefront of evidence-based product development.”

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

1551807154_andrew.jpg


Register here to be notified of future Company articles
View full profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.